Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability study of seladelpar in primary biliary cholangitis
NL-OMON59942Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Gilead Sciences. Primary endpoints: Treatment-emergent adverse events, Biochemistry results and 1 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON59942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59942.